title: Akt activation protects pancreatic beta cells from AMPK-mediated death through stimulation of mTOR.
abstract: Sustained activation of AMP-activated protein kinase (AMPK) induces apoptosis in several cell types. In pancreatic beta cells this occurs under glucose limitation, or in the presence of the pharmacological AMPK activator 5-aminoimidazole-4-carboxamide-riboside (AICAR). It is unknown whether Akt activation can counteract AMPK-mediated apoptosis, nor whether mTOR activation downstream of Akt mediates any survival signal in these conditions. We report that expression of a constitutively active form of Akt increases mTOR activity and prevents apoptosis upon AMPK activation. Akt-mediated survival was inhibited by rapamycin. Expression of a constitutively active form of the mTOR target ribosomal protein S6 kinase (S6K) or of translation factor eIF4E reduced apoptosis by glucose limitation, and co-expression of S6K and eIF4E protected beta cells to the same extent as active Akt. The protective effects of active Akt and S6K were associated with increased cellular protein synthesis activity. It is concluded that Akt stimulation of mTOR and subsequent activation of the targets by which mTOR affects protein translation are required and sufficient mechanisms for Akt-mediated survival of beta cells undergoing sustained AMPK activation.
authors: Diabetes Research Center, Brussels Free University, VUB, Partner of the Juvenile Diabetes Research Center for Beta Cell Therapy in Europe, Laarbeeklaan 103, B-1090 Brussels, Belgium.
authors: Ying
authors: Y
authors: Cai
authors: Qidi
authors: Q
authors: Wang
authors: Zhidong
authors: Z
authors: Ling
authors: Daniel
authors: D
authors: Pipeleers
authors: Paul
authors: P
authors: McDermott
authors: Mario
authors: M
authors: Pende
authors: Harry
authors: H
authors: Heimberg
authors: Mark
authors: M
authors: Van de Casteele
mesh_terms: D055372:AMP-Activated Protein Kinases; D000818:Animals; D017209:Apoptosis; D002460:Cell Line; D002470:Cell Survival; D002478:Cells, Cultured; D039561:Eukaryotic Initiation Factor-4E / Q000378:metabolism; D050417:Insulin-Secreting Cells / Q000166:cytology / Q000378:metabolism*; D009097:Multienzyme Complexes / Q000378:metabolism*; D011494:Protein Kinases / Q000378:metabolism*; D017346:Protein Serine-Threonine Kinases / Q000378:metabolism*; D051057:Proto-Oncogene Proteins c-akt / Q000378:metabolism*; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000378:metabolism; D051381:Rats; D038762:Ribosomal Protein S6 Kinases, 70-kDa / Q000378:metabolism; D058570:TOR Serine-Threonine Kinases
chemical_list: D039561:Eukaryotic Initiation Factor-4E; D009097:Multienzyme Complexes; D019253:Proto-Oncogene Proteins c-bcl-2; D011494:Protein Kinases; D017346:Protein Serine-Threonine Kinases; D051057:Proto-Oncogene Proteins c-akt; D038762:Ribosomal Protein S6 Kinases, 70-kDa; D058570:TOR Serine-Threonine Kinases; D055372:AMP-Activated Protein Kinases